Jadestone Clinical Research LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$98,771	11
2024	Research	$1,695,445	53
2023	Research	$1,337,416	63
2022	Research	$881,498	30

Breakdown

Who paid Research payments · program years 2022–2025

Pfizer Inc. $3,671,922 93 payments
CSL Behring $208,310 61 payments
Invivyd Inc $132,897 3 payments

Studies the money was for Research payments · program years 2022–2025

A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $2,118,349 27 payments
A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $840,481 15 payments
A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $383,577 17 payments
A Phase 3 Master Protocol to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults at High Risk of Severe RSV Disease $258,517 16 payments
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis $208,310 61 payments
Canopy $132,897 3 payments
A Phase 3 Multicenter Parallelgroup Openlabel Study to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine When Coadministered With Herpes Zoster Subunit Vaccine in Adults 50 Years of Age $31,110 7 payments
A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $15,500 1 payment
An Interventional Efficacy and Safety Phase 3 Randomized Doubleblind 3Arm Study to Investigate Ibuzatrelvir in Adults With Symptomatic Covid19 Who Are Severely Immunocompromised $12,283 1 payment
An Interventional Efficacy and Safety Phase 3 Doubleblind 2Arm Study to Investigate Orally Administered Ibuzatrelvir Compared With Placebo in Nonhospitalized Symptomatic Adult and Adolescent Participants With Covid19 Who Are at High Risk of Progressing to Severe Illness $11,034 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.